Antimicrobial Resistance: Causes, Consequences & Solutions

Introduction

Today, antimicrobial resistance (AMR) has emerged as one of the most pressing public health threats of the 21st century, with far-reaching consequences that extend beyond the realm of healthcare. Startling figures released by the U.S. Centers for Disease Control and Prevention (CDC) underscore the severity of this issue, revealing that AMR claimed at least 1.27 million lives annually and was implicated in nearly 5 million deaths worldwide in 2019 alone (About Antimicrobial Resistance, 2024). More recently, the CDC reports that about 2 million Americans contract AMR infections each year, leading to a minimum of 23,000 fatalities in the U.S. annually. Further, future estimates suggest that antimicrobial resistance could result in a $100 trillion decrease in global GDP by 2050, highlighting the enormous economic impact of these trends (Jiang et al., 2024).

Taken together, it is clear that as microorganisms of all types continue to evolve to withstand the effects of antibiotics and other antimicrobial agents, the world faces a potential future where once-treatable infections become increasingly difficult, if not impossible, to combat. The purpose of this paper is to critically analyze the multifaceted nature of AMR as a public health menace and propose innovative strategies to address this growing concern. Following this analysis, the paper provides a summary of the key findings in the conclusion.

Understanding Antimicrobial Resistance

In the year 2135, Earth was a planet teetering on the brink of annihilation. Humanity, once the dominant force, had been humbled by an invisible enemy. Although global warming had caused catastrophic damage around the world, it was antimicrobial resistance that had ravaged the globe, stripping modern medicine of its ability to cure or even treat infections. Hospitals, once bustling with the hum of healing, now echoed with the cries of the dying. The few remaining humans, terrified of even scratching themselves, held onto the faint hope that someday, somehow, life would find a way to endure — but in the year 2135, that hope was but a faint whisper in the dark. Like the fate of the Martian invaders in H. G. Wells' War of the Worlds, in the end, it was not a cataclysmic event or a war that brought humanity to its knees, but the tiniest of its many historic adversaries.

Unfortunately, the grim scenario described above may become an even grimmer reality in the foreseeable future. According to the definition provided by Toghroli et al. (2024), the term "antimicrobial resistance (AMR)" refers to "the reduced effectiveness of antimicrobial agents, such as antibiotics, antivirals, antifungals, and antiparasitics, against infections caused by bacteria, viruses, fungi, and parasites" (p. 2). In other words, virtually any drug currently used to treat infections can lose its potency and efficacy over time due to AMR. It is important to note that, at its core, AMR is a natural phenomenon that occurs when microorganisms — such as bacteria, viruses, fungi, and parasites — develop the ability to resist the effects of antimicrobial drugs designed to eliminate them (Toghroli et al., 2024).

Although naturally occurring, this process is accelerated by the misuse and overuse of antibiotics, both in human medicine and animal agriculture. In this regard, Jiang et al. (2024) note that "due to the overuse of antimicrobial medications, a growing number of pathogens have developed resistance to one or multiple antimicrobial agents" (p. 2). Not surprisingly, the widespread availability and frequently indiscriminate prescription of antibiotics have created a selective pressure that favors the survival and proliferation of resistant strains. Moreover, the extensive use of antibiotics in livestock farming for growth promotion and disease prevention has contributed to the development and spread of AMR in animal populations, with the potential for transmission to humans through the food chain or environmental contamination (Jangsangthong et al., 2024).

Consequences and Economic Burden of AMR

The consequences of AMR are far-reaching and extend beyond the direct impact on human health. As infections become harder to treat, patients face prolonged illnesses, increased morbidity, and a higher risk of complications and death. This burden is particularly acute in low- and middle-income countries, where access to second-line or newer antibiotics may be limited and healthcare infrastructure is already frequently inadequate (Salam et al., 2023). Furthermore, AMR places a significant strain on healthcare systems, as patients require longer hospital stays, more intensive care, and costlier treatments (Gilham et al., 2024). As noted above, the economic implications are staggering: by 2050, AMR could cost the global economy up to $100 trillion — roughly four times the current U.S. annual GDP — and push an additional 28 million Americans into poverty (Jiang et al., 2024).

Clearly, the clock is ticking, but like the existential threats of climate change, extremism, and nuclear war, efforts to combat AMR to date have failed to keep pace with the problem. Unlike those other threats, AMR remains "the silent killer" stalking the future health of the nation. This also means that otherwise-preventable diseases are creating an enormous burden on the nation's healthcare consumers and already scarce resources.

Strategies to Combat AMR

To address the complex challenge of AMR, a comprehensive and multisectoral approach is essential. Falgarona (2024) emphasizes that "AMR is a complex global problem with no single cause — and no single, easy solution. The COVID-19 pandemic showed us what we can achieve when governments, international bodies and industries set clear priorities and cooperate on shared goals, and the same approach must be applied to the AMR crisis" (para. 7).

First and foremost, there is an urgent need to promote the judicious use of antibiotics in both human and animal health. Although awareness of the problem of AMR has been raised in the healthcare community in recent years, the standard "go-to" solution for far too many healthcare practitioners remains the prescription of some type of antibiotic for a wide array of disorders (Gilham et al., 2024). For example, a seminal study by a university school of medicine noted that in response to a hypothetical situation involving asymptomatic bacteriuria — a condition without any UTI symptoms where bacteria are detected in patients' urine — fully "71 percent of clinicians, 392 out of the 551 who completed the survey, would opt to treat such a patient with antibiotics even though such treatment goes against the recommended guidelines" (Kotz, 2022, para. 4).

The more judicious use of antibiotics can be achieved through the development and implementation of evidence-based prescribing guidelines, together with high-profile education and awareness campaigns targeting healthcare professionals as well as the general public (Gilham et al., 2024). In addition, antimicrobial stewardship programs — which aim to optimize antibiotic use and minimize the development of resistance — should be strengthened and expanded across all healthcare settings. In the agricultural sector, the use of antibiotics for growth promotion should be phased out, and their use for disease prevention should be more strictly regulated and monitored (Kim et al., 2024).

Innovative solutions are also needed to incentivize the development of new antibiotics and alternative therapies. The current market model for antibiotic development is broken, with pharmaceutical companies frequently reluctant to invest in the costly and risky process of bringing new drugs to market given the limited financial returns. To address this, novel funding mechanisms — such as public-private partnerships, subsidies, and incentives for research and development — must be explored (Kim et al., 2024).

Phage Therapy as a Promising Alternative

Phage therapy may be the next breakthrough that can supplement or even replace antibiotics and other conventional infection treatments in the future. Bacteriophages, or phages, are viruses that specifically infect and kill bacteria, offering a promising solution to the growing problem of antibiotic-resistant infections (Hibstu et al., 2022). Unlike broad-spectrum antibiotics, phages are highly specific, targeting only the bacteria they are meant to destroy while leaving beneficial microbes unharmed. This specificity minimizes the collateral damage to the body's microbiome, which is frequently a significant downside of traditional antibiotic treatments (Hibstu et al., 2022).

Phage therapy leverages the natural predatory relationship between phages and bacteria to achieve these outcomes. Wang et al. (2024) report that "recently, phage therapy has been revitalized as a promising strategy to address the challenges posed by bacterial infections in the era of antibiotic resistance. The use of phage therapy in treating infectious diseases has demonstrated positive results" (p. 37). Likewise, a study by Hibstu et al. (2022) notes that phage therapy is a promising alternative for treating infections caused by bacteria, including those resistant to antibiotics, with minimal or no toxicity to patients.

It is noteworthy that this approach was first introduced approximately a century ago, but the rapid increase in bacterial antimicrobial resistance — leading to significant morbidity, mortality, and economic burden — has sparked renewed interest in phage therapy. This treatment involves the use of live lytic phages, genetically engineered phages, or phage-derived biological products to combat bacterial infections. Notably, phages are naturally cleared from the body within a week of resolving the infection and are highly specific, targeting particular bacterial strains while minimally disrupting the human microbial balance (Hibstu et al., 2022).

Prior to any therapeutic use, phages must undergo thorough screening to ensure the absence of resistance genes, virulence factors, cytotoxicity, and any adverse interactions with host tissues or organs. As phages are immunogenic — meaning they have the ability to provoke an immune response in the human body — administering high titers for therapy exposes them to the host immune system, potentially triggering an immune response. It is especially noteworthy that, to date, no severe adverse effects have been reported in association with human phage therapy (Hibstu et al., 2022).

Unlike conventional infection treatments, phage therapy operates in ways that can not only destroy harmful cells but evolve alongside them. When a phage encounters a susceptible bacterial cell, it attaches to the cell surface, injects its genetic material, and hijacks the bacterial machinery to produce more phages. This process ultimately leads to the lysis — or bursting — of the bacterial cell, releasing new phages to continue the cycle (Wang et al., 2024). One of the significant advantages of phage therapy is its ability to evolve alongside bacteria. While bacteria can develop resistance to phages, phages can also mutate to overcome these defenses, thereby creating a dynamic and adaptive approach to bacterial infections not currently available through conventional means (Wang et al., 2024).

Some of the novel concepts in phage therapy include the direct treatment of bacterial infections, phage-mediated prevention of bacterial infection, and the exploration of phage diversity in environmental and human ecological niches (Hibstu et al., 2022).

Besides its notable lack of toxic effects on humans, phage therapy has also shown promising results in a variety of settings, including the treatment of chronic wounds, respiratory infections, and gastrointestinal diseases. Phage therapy has been particularly effective against biofilms — structured communities of bacteria that are notoriously resistant to antibiotics. Kovacs et al. (2024) report that "bacteria further their pathogenicity because of their ability to form biofilms on wounds, medical devices, and implant surfaces. Methods for treating biofilms in clinical settings are limited, and when formed by antibiotic-resistant bacteria, can generate chronic infections that are recalcitrant to available therapies" (p. e1294). Phages can also be engineered to enhance their efficacy, stability, and delivery, making them even more potent against resistant strains (Kovacs et al., 2024).

Despite its potential for treating infections of all types, phage therapy faces several challenges before it can become a mainstream treatment. Regulatory hurdles, the need for extensive clinical trials, and the complexity of phage-bacteria interactions require thorough research and development. Furthermore, personalized phage therapy necessitates the rapid identification and matching of phages to specific bacterial infections, which can be logistically demanding.

Conclusion

The research showed that antimicrobial resistance has emerged as yet another existential threat for humanity but, unlike global warming or nuclear war, the general public and even far too many healthcare practitioners remain unaware of this looming threat. In sum, AMR represents an urgent and formidable threat to global public health, demanding a concerted and multifaceted response. Despite the challenges, by promoting the judicious use of antibiotics, incentivizing innovation, strengthening surveillance, improving IPC practices, and engaging communities, it is possible to work toward a future where effective antimicrobials remain a cornerstone of modern medicine.

The path ahead, however, is fraught with challenges, requiring sustained political will, financial investment, and global cooperation. As the world continues to grapple with climate change and the ongoing aftermath of the COVID-19 pandemic, it is crucial not to lose sight of the looming crisis of AMR. The time for action is now, and the stakes could not be higher. By harnessing humankind's collective wisdom, ingenuity, and resolve, the research also showed that it is possible to safeguard the effectiveness of antimicrobials for generations to come and ensure that the silent pandemic of AMR does not become the nightmarish 2135 scenario described at the outset of this paper.